ID   FDH_CANBO               Reviewed;         364 AA.
AC   O13437; O93968; Q00498; Q1PAH3;
DT   18-MAY-2010, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   07-APR-2021, entry version 98.
DE   RecName: Full=Formate dehydrogenase {ECO:0000255|HAMAP-Rule:MF_03210, ECO:0000312|EMBL:CAB54834.1};
DE            Short=FDH {ECO:0000255|HAMAP-Rule:MF_03210};
DE            EC=1.17.1.9 {ECO:0000255|HAMAP-Rule:MF_03210, ECO:0000269|PubMed:10691964, ECO:0000269|PubMed:11171126, ECO:0000269|PubMed:1248477, ECO:0000269|PubMed:17525463, ECO:0000269|PubMed:9226256};
DE   AltName: Full=NAD-dependent formate dehydrogenase {ECO:0000255|HAMAP-Rule:MF_03210, ECO:0000312|EMBL:AAC49766.1};
GN   Name=FDH1 {ECO:0000303|PubMed:9226256, ECO:0000312|EMBL:AAC49766.1};
GN   Synonyms=FDH {ECO:0000312|EMBL:CAA09466.2},
GN   FDH3 {ECO:0000312|EMBL:CAB54834.1};
OS   Candida boidinii (Yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina; Saccharomycetes;
OC   Saccharomycetales; Pichiaceae; Ogataea; Ogataea/Candida clade.
OX   NCBI_TaxID=5477;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-25.
RC   STRAIN=ATCC 56294 / CBS 8030 / CCRC 21757 / NRRL Y-17325;
RX   PubMed=7557425; DOI=10.1016/0378-1119(95)00347-9;
RA   Allen S.J., Holbrook J.J.;
RT   "Isolation, sequence and overexpression of the gene encoding NAD-dependent
RT   formate dehydrogenase from the methylotrophic yeast Candida methylica.";
RL   Gene 162:99-104(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 2-45; 57-76; 87-103;
RP   190-201; 207-236; 242-246; 292-326 AND 329-354, FUNCTION, CATALYTIC
RP   ACTIVITY, DISRUPTION PHENOTYPE, AND INDUCTION.
RC   STRAIN=S2 {ECO:0000312|EMBL:AAC49766.1};
RX   PubMed=9226256; DOI=10.1128/jb.179.14.4480-4485.1997;
RA   Sakai Y., Murdanoto A.P., Konishi T., Iwamatsu A., Kato N.;
RT   "Regulation of the formate dehydrogenase gene, FDH1, in the methylotrophic
RT   yeast Candida boidinii and growth characteristics of an FDH1-disrupted
RT   strain on methanol, methylamine, and choline.";
RL   J. Bacteriol. 179:4480-4485(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 1-15, CATALYTIC ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, BIOTECHNOLOGY, AND MUTAGENESIS OF CYS-23 AND
RP   CYS-262.
RC   STRAIN=ATCC 32195 {ECO:0000312|EMBL:CAB54834.1};
RX   PubMed=10691964; DOI=10.1046/j.1432-1327.2000.01123.x;
RA   Slusarczyk H., Felber S., Kula M.R., Pohl M.;
RT   "Stabilization of NAD-dependent formate dehydrogenase from Candida boidinii
RT   by site-directed mutagenesis of cysteine residues.";
RL   Eur. J. Biochem. 267:1280-1289(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 1-30 AND 132-140, CATALYTIC
RP   ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF PHE-69;
RP   ASN-119; ILE-175; GLN-197; ARG-258; GLN-287; PRO-288 AND HIS-311.
RC   STRAIN=NCYC 1513 {ECO:0000312|EMBL:CAA09466.2};
RX   PubMed=11171126; DOI=10.1042/0264-6021:3540455;
RA   Labrou N.E., Rigden D.J.;
RT   "Active-site characterization of Candida boidinii formate dehydrogenase.";
RL   Biochem. J. 354:455-463(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=2.2159 {ECO:0000312|EMBL:ABE69165.2};
RA   Zhang G., Yang G., Cao Z., Liu M.;
RL   Submitted (JUL-2007) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   PROTEIN SEQUENCE OF 357-363, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS
RP   OF LYS-360.
RX   PubMed=11054119; DOI=10.1046/j.1432-1327.2000.01761.x;
RA   Labrou N.E., Rigden D.J., Clonis Y.D.;
RT   "Characterization of the NAD+ binding site of Candida boidinii formate
RT   dehydrogenase by affinity labelling and site-directed mutagenesis.";
RL   Eur. J. Biochem. 267:6657-6664(2000).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND SUBUNIT.
RX   PubMed=1248477; DOI=10.1111/j.1432-1033.1976.tb10108.x;
RA   Schute H., Flossdorf J., Sahm H., Kula M.R.;
RT   "Purification and properties of formaldehyde dehydrogenase and formate
RT   dehydrogenase from Candida boidinii.";
RL   Eur. J. Biochem. 62:151-160(1976).
RN   [8]
RP   BIOTECHNOLOGY.
RX   DOI=10.1002/ceat.270170211;
RA   Weuster-Botz D., Paschold H., Striegel B., Gieren H., Kula M.R.,
RA   Wandrey C.;
RT   "Continuous computer controlled production of formate dehydrogenase (FDH)
RT   and isolation on a pilot scale.";
RL   Chem. Eng. Technol. 17:131-137(1994).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF MUTANT GLU-47 AND (1.55 ANGSTROMS)
RP   OF MUTANT VAL-328, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   SUBUNIT, CATALYTIC AND COENZYME-BINDING REGIONS, AND MUTAGENESIS OF LYS-47
RP   AND LYS-328.
RX   PubMed=17525463; DOI=10.1110/ps.062741707;
RA   Schirwitz K., Schmidt A., Lamzin V.S.;
RT   "High-resolution structures of formate dehydrogenase from Candida
RT   boidinii.";
RL   Protein Sci. 16:1146-1156(2007).
CC   -!- FUNCTION: Catalyzes the NAD(+)-dependent oxidation of formate to carbon
CC       dioxide. Formate oxidation is the final step in the methanol oxidation
CC       pathway in methylotrophic microorganisms. Has a role in the
CC       detoxification of exogenous formate in non-methylotrophic organisms.
CC       {ECO:0000255|HAMAP-Rule:MF_03210, ECO:0000269|PubMed:1248477,
CC       ECO:0000269|PubMed:9226256}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=formate + NAD(+) = CO2 + NADH; Xref=Rhea:RHEA:15985,
CC         ChEBI:CHEBI:15740, ChEBI:CHEBI:16526, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57945; EC=1.17.1.9; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_03210, ECO:0000269|PubMed:10691964,
CC         ECO:0000269|PubMed:11171126, ECO:0000269|PubMed:1248477,
CC         ECO:0000269|PubMed:17525463, ECO:0000269|PubMed:9226256};
CC   -!- ACTIVITY REGULATION: Cu(2+), Hg and p-chloromercuribenzoate are strong
CC       inhibitors of enzyme activity and Ca(2+), Mg(2+), Zn(2+), Mn(2+),
CC       Cd(2+) and Sn(2+) have no effect on activity indicating a cysteine
CC       residue in the protein is essential for enzyme activity or to maintain
CC       the proper structure of the enzyme. Nitrite and nitrate inhibit some
CC       enzyme activity, however cyanide, azide, thiocyanate and cyanate are
CC       strong inhibitors of the enzymatic reaction. The inhibition of cyanide
CC       is competitive with formate and reversible.
CC       {ECO:0000269|PubMed:1248477}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=13 mM for formate (at 30 degrees Celsius and at pH 7.5)
CC         {ECO:0000269|PubMed:1248477};
CC         KM=0.09 mM for NAD (at 30 degrees Celsius and at pH 7.5)
CC         {ECO:0000269|PubMed:1248477};
CC         KM=5.6 mM for formate (at 30 degrees Celsius and at pH 7.5)
CC         {ECO:0000269|PubMed:10691964};
CC         KM=0.045 mM for NAD (at 30 degrees Celsius and at pH 7.5)
CC         {ECO:0000269|PubMed:10691964};
CC         KM=2.42 mM for formate (at 25 degrees Celsius and at pH 7.5)
CC         {ECO:0000269|PubMed:11171126};
CC         KM=0.04 mM for NAD (at 25 degrees Celsius and at pH 7.5)
CC         {ECO:0000269|PubMed:11171126};
CC         KM=2.4 mM for formate (at 25 degrees Celsius and at pH 7.6)
CC         {ECO:0000269|PubMed:11054119};
CC         KM=0.04 mM for NAD (at 25 degrees Celsius and at pH 7.6)
CC         {ECO:0000269|PubMed:11054119};
CC         KM=20.0 mM for formate (at 20 degrees Celsius, at pH 7.5 and after 2
CC         weeks of storage at 4 degrees Celsius in GF buffer)
CC         {ECO:0000269|PubMed:17525463};
CC         KM=0.05 mM for NAD (at 20 degrees Celsius, at pH 7.5 and after 2
CC         weeks of storage at 4 degrees Celsius in GF buffer)
CC         {ECO:0000269|PubMed:17525463};
CC         KM=35.0 mM for formate (at 20 degrees Celsius, at pH 7.5 and after 4
CC         months of storage at 4 degrees Celsius in GF buffer)
CC         {ECO:0000269|PubMed:17525463};
CC         KM=0.09 mM for NAD (at 20 degrees Celsius, at pH 7.5 and after 4
CC         months of storage at 4 degrees Celsius in GF buffer)
CC         {ECO:0000269|PubMed:17525463};
CC         Vmax=6 uM/min/mg enzyme {ECO:0000269|PubMed:10691964};
CC       pH dependence:
CC         Optimum pH is 7.5-8.5. {ECO:0000269|PubMed:10691964,
CC         ECO:0000269|PubMed:11054119, ECO:0000269|PubMed:11171126,
CC         ECO:0000269|PubMed:1248477, ECO:0000269|PubMed:17525463};
CC       Temperature dependence:
CC         Broad temperature optima between 45 and 55 degrees Celsius. Reaction
CC         rate increases steeply up to 55 degrees Celsius. 50% of activity lost
CC         after incubation for 20 minutes at 57 degrees Celsius. Thermal
CC         stability increases in the presence of glycerol.
CC         {ECO:0000269|PubMed:10691964, ECO:0000269|PubMed:11054119,
CC         ECO:0000269|PubMed:11171126, ECO:0000269|PubMed:1248477,
CC         ECO:0000269|PubMed:17525463};
CC   -!- SUBUNIT: Homodimer. {ECO:0000255|HAMAP-Rule:MF_03210,
CC       ECO:0000269|PubMed:1248477, ECO:0000269|PubMed:17525463}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_03210}.
CC   -!- INDUCTION: Expression is strongly induced by methanol, but is
CC       completely repressed in the presence of glucose. However, methanol
CC       induced expression is equally strong in cells grown on glucose when
CC       formate, methylamine or choline is added. No expression is detected in
CC       cells grown on glycerol. When formate, methylamine or choline is added
CC       to the culture medium of glycerol- or glucose-grown cells, they exhibit
CC       an induction of FDH1 expression. {ECO:0000269|PubMed:9226256}.
CC   -!- DISRUPTION PHENOTYPE: Is able to grow on methanol in a batch culture
CC       experiment, but its growth is greatly inhibited and a toxic level of
CC       formate accumulates in the medium. Formate is not detected in the
CC       medium in a methanol-limited chemostat culture but deletion mutant
CC       shows only one-fourth of the growth yield of the wild-type.
CC       {ECO:0000269|PubMed:9226256}.
CC   -!- BIOTECHNOLOGY: Ideal catalyst for synthesizing chiral compounds of high
CC       enantiomeric purity from prochiral precursors due to a favorable
CC       thermodynamic equilibrium, the oxidation of formate to carbon dioxide
CC       while also reducing NAD to NADH. However, the necessesity for the
CC       presence of large quantities of the enzyme and its rapid inactivation
CC       under biotransformation conditions results in higher costs for the
CC       biocatalyst industry. In order to make this enzymatic reduction viable
CC       and to perform it on a larger scale a more efficient and cost effective
CC       process has been established. Site-directed mutagenesis has been
CC       effective in stabilizing this commercially important enzyme for its
CC       application in the biotransformation of trimethyl pyruvate to L-tert
CC       leucine. {ECO:0000269|PubMed:10691964, ECO:0000269|Ref.8}.
CC   -!- SIMILARITY: Belongs to the D-isomer specific 2-hydroxyacid
CC       dehydrogenase family. FDH subfamily. {ECO:0000255|HAMAP-Rule:MF_03210}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X81129; CAA57036.1; -; Genomic_DNA.
DR   EMBL; AF004096; AAC49766.1; -; Genomic_DNA.
DR   EMBL; AJ245934; CAB54834.1; -; Genomic_DNA.
DR   EMBL; AJ011046; CAA09466.2; -; Genomic_DNA.
DR   EMBL; DQ458777; ABE69165.2; -; Genomic_DNA.
DR   PIR; JC4252; JC4252.
DR   PDB; 2FSS; X-ray; 1.70 A; A/B/C/D=2-364.
DR   PDB; 2J6I; X-ray; 1.55 A; A/B/C/D=2-364.
DR   PDBsum; 2FSS; -.
DR   PDBsum; 2J6I; -.
DR   SMR; O13437; -.
DR   OrthoDB; 700058at2759; -.
DR   BioCyc; MetaCyc:MONOMER-17206; -.
DR   BRENDA; 1.2.1.2; 1100.
DR   SABIO-RK; O13437; -.
DR   EvolutionaryTrace; O13437; -.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0009326; C:formate dehydrogenase complex; IEA:UniProtKB-EC.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008863; F:formate dehydrogenase (NAD+) activity; IDA:UniProtKB.
DR   GO; GO:0070403; F:NAD+ binding; IDA:UniProtKB.
DR   GO; GO:0016616; F:oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor; IEA:InterPro.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042426; P:choline catabolic process; IMP:UniProtKB.
DR   GO; GO:0042183; P:formate catabolic process; IDA:UniProtKB.
DR   GO; GO:0015946; P:methanol oxidation; IMP:UniProtKB.
DR   GO; GO:0030416; P:methylamine metabolic process; IMP:UniProtKB.
DR   GO; GO:0006734; P:NADH metabolic process; IMP:UniProtKB.
DR   GO; GO:0006735; P:NADH regeneration; IDA:UniProtKB.
DR   CDD; cd05302; FDH; 1.
DR   HAMAP; MF_03210; Formate_dehydrogenase; 1.
DR   InterPro; IPR006139; D-isomer_2_OHA_DH_cat_dom.
DR   InterPro; IPR029753; D-isomer_DH_CS.
DR   InterPro; IPR029752; D-isomer_DH_CS1.
DR   InterPro; IPR006140; D-isomer_DH_NAD-bd.
DR   InterPro; IPR033689; FDH_NAD-dep.
DR   InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR   Pfam; PF00389; 2-Hacid_dh; 1.
DR   Pfam; PF02826; 2-Hacid_dh_C; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS00065; D_2_HYDROXYACID_DH_1; 1.
DR   PROSITE; PS00670; D_2_HYDROXYACID_DH_2; 1.
DR   PROSITE; PS00671; D_2_HYDROXYACID_DH_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cytoplasm; Direct protein sequencing; NAD;
KW   Nucleotide-binding; Oxidoreductase.
FT   CHAIN           1..364
FT                   /note="Formate dehydrogenase"
FT                   /id="PRO_0000393949"
FT   NP_BIND         174..175
FT                   /note="NAD"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210"
FT   NP_BIND         230..234
FT                   /note="NAD"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210"
FT   NP_BIND         311..314
FT                   /note="NAD"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210"
FT   REGION          2..119
FT                   /note="Catalytic"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210,
FT                   ECO:0000269|PubMed:17525463"
FT   REGION          120..312
FT                   /note="Coenzyme-binding"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210,
FT                   ECO:0000269|PubMed:17525463"
FT   REGION          313..358
FT                   /note="Catalytic"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210,
FT                   ECO:0000269|PubMed:17525463"
FT   BINDING         93
FT                   /note="Substrate; via amide nitrogen"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210"
FT   BINDING         119
FT                   /note="Substrate"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210"
FT   BINDING         195
FT                   /note="NAD"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210"
FT   BINDING         256
FT                   /note="NAD; via carbonyl oxygen"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210"
FT   BINDING         282
FT                   /note="NAD"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210"
FT   SITE            258
FT                   /note="Important for catalytic activity"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210,
FT                   ECO:0000305|PubMed:17525463"
FT   SITE            311
FT                   /note="Important for catalytic activity"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03210,
FT                   ECO:0000305|PubMed:17525463"
FT   VARIANT         9
FT                   /note="D -> G (in strain: 2.2159)"
FT                   /evidence="ECO:0000305, ECO:0000312|EMBL:ABE69165.2"
FT   VARIANT         50..51
FT                   /note="ET -> GN (in strain: 2.2159 and NCYC 1513)"
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   VARIANT         53
FT                   /note="E -> V (in strain: 2.2159 and NCYC 1513)"
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   VARIANT         56
FT                   /note="K -> Q (in strain: 2.2159 and NCYC 1513)"
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   VARIANT         79
FT                   /note="L -> I (in strain: 2.2159 and NCYC 1513)"
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   VARIANT         84
FT                   /note="N -> K (in strain: 2.2159 and NCYC 1513)"
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   VARIANT         87
FT                   /note="L -> S (in strain ATCC 56294 / CBS 8030 / CCRC 21757
FT                   / NRRL Y-17325)"
FT                   /evidence="ECO:0000269|PubMed:7557425"
FT   VARIANT         108
FT                   /note="K -> R (in strain: 2.2159)"
FT                   /evidence="ECO:0000305, ECO:0000312|EMBL:ABE69165.2"
FT   VARIANT         145
FT                   /note="I -> N (in strain: 2.2159)"
FT                   /evidence="ECO:0000305, ECO:0000312|EMBL:ABE69165.2"
FT   VARIANT         184
FT                   /note="L -> V (in strain: 2.2159 and NCYC 1513)"
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   VARIANT         202
FT                   /note="E -> D (in strain: 2.2159 and NCYC 1513)"
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   VARIANT         308
FT                   /note="M -> T (in strain: 2.2159)"
FT                   /evidence="ECO:0000305, ECO:0000312|EMBL:ABE69165.2"
FT   VARIANT         325
FT                   /note="E -> Q (in strain: 2.2159 and NCYC 1513)"
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         23
FT                   /note="C->S: Slight increase in substrate affinity for
FT                   formate but no change in affinity for NAD, 9 degrees
FT                   Celsius decrease in thermal stability compared to the wild-
FT                   type, significantly higher stability compared to wild-type
FT                   under biotransformation conditions, significantly more
FT                   stable in the presence of CuCl(2); when associated with A-
FT                   262. Large increase in substrate affinity for formate but
FT                   no significant change in affinity for NAD, 13 degrees
FT                   Celsius decrease in thermal stability compared to the wild-
FT                   type, significantly more stable in the presence of CuCl(2);
FT                   when associated with V-262. No significant change in
FT                   affinity for formate or NAD, 5 degrees Celsius decrease in
FT                   thermal stability compared to the wild-type, significantly
FT                   higher stability compared to wild-type under
FT                   biotransformation conditions, and significantly more stable
FT                   in the presence of CuCl(2)."
FT                   /evidence="ECO:0000269|PubMed:10691964"
FT   MUTAGEN         47
FT                   /note="K->E: Slight increase in substrate affinity for
FT                   formate and also affinity for NAD increases by half after 2
FT                   weeks. Also after 4 months affinity for formate increases
FT                   by more than half and affinity for NAD increases by more
FT                   than half. Retains 84% of residual activity after
FT                   incubation for 20 minutes at a thermal inactivation
FT                   temperature of 55 degrees Celsius in samples stored for 2
FT                   weeks compared to wild-type which loses 50% of its activity
FT                   at 55 degrees Celsius."
FT                   /evidence="ECO:0000269|PubMed:17525463"
FT   MUTAGEN         69
FT                   /note="F->A: 2-fold decrease in substrate affinity for
FT                   formate, but no significant change in affinity for NAD. A
FT                   significant reduction in catalytic activity compared to the
FT                   wild-type."
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         119
FT                   /note="N->A: 94-fold decrease in substrate affinity for
FT                   formate and 2700-fold decrease in substrate affinity for
FT                   NAD. A significant reduction in catalytic activity compared
FT                   to the wild-type; when associated with A-311."
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         119
FT                   /note="N->H: 80-fold decrease in substrate affinity for
FT                   formate and a 1250-fold decrease in substrate affinity for
FT                   NAD. A significant reduction in catalytic activity compared
FT                   to the wild-type."
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         175
FT                   /note="I->A: 2-fold decrease in substrate affinity for
FT                   formate and a 12-fold decrease in substrate affinity for
FT                   NAD. A significant reduction in catalytic activity compared
FT                   to the wild-type."
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         197
FT                   /note="Q->L: 4-fold decrease in substrate affinity for
FT                   formate but no significant change in affinity for NAD
FT                   compared to the wild-type."
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         258
FT                   /note="R->A: No catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         262
FT                   /note="C->A: Slight increase in substrate affinity for
FT                   formate but no change in affinity for NAD, 9 degrees
FT                   Celsius decrease in thermal stability compared to the wild-
FT                   type, greater stability at a higher pH compared to the
FT                   wild-type; when associated with S-23."
FT                   /evidence="ECO:0000269|PubMed:10691964"
FT   MUTAGEN         262
FT                   /note="C->V: Large increase in substrate affinity for
FT                   formate but no significant change in affinity for NAD, 13
FT                   degrees Celsius decrease in thermal stability compared to
FT                   the wild-type; when associated with S-23. Great increase in
FT                   substrate affinity for formate and NAD and 8 degrees
FT                   Celsius decrease in thermal stability compared to the wild-
FT                   type."
FT                   /evidence="ECO:0000269|PubMed:10691964"
FT   MUTAGEN         287
FT                   /note="Q->A: 2-fold decrease in substrate affinity for
FT                   formate and 3-fold decrease in substrate affinity for NAD
FT                   compared to the wild-type; when associated with A-311."
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         287
FT                   /note="Q->E: 380-fold decrease in substrate affinity for
FT                   formate and 3-fold decrease in substrate affinity for NAD
FT                   compared to the wild-type; when associated with T-288. No
FT                   significant decrease in substrate affinity for formate but
FT                   a 4-fold decrease in substrate affinity for NAD and a
FT                   significant reduction in catalytic activity compared to the
FT                   wild-type, a more acidic pH is seen than in the wild-type,
FT                   preventing formate binding by a single ionization of a
FT                   group compared to that of the wild-type."
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         288
FT                   /note="P->T: 380-fold decrease in substrate affinity for
FT                   formate and 3-fold decrease in substrate affinity for NAD
FT                   compared to the wild-type; when associated with E-287."
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         311
FT                   /note="H->A: 2-fold decrease in substrate affinity for
FT                   formate and 3-fold decrease in substrate affinity for NAD
FT                   compared to the wild-type; when associated with A-287. 93-
FT                   fold decrease in substrate affinity for formate and 2700-
FT                   fold decrease in substrate affinity for NAD, and a
FT                   significant reduction in catalytic activity compared to the
FT                   wild-type; when associated with A-119."
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         311
FT                   /note="H->Q: 10-fold decrease in substrate affinity for
FT                   formate and significant reduction in the catalytic activity
FT                   compared to the wild-type."
FT                   /evidence="ECO:0000269|PubMed:11171126"
FT   MUTAGEN         328
FT                   /note="K->V: A 75% increase in substrate affinity for
FT                   formate after 2 weeks and a 50% increase in affinity for
FT                   NAD. However, after 4 months the affinity for formate
FT                   increases 7-fold and affinity for NAD increases by 2
FT                   thirds. Retains 70% of residual activity after incubation
FT                   for 20 minutes at a thermal inactivation temperature of 55
FT                   degrees Celsius in samples stored for 2 weeks compared to
FT                   wild-type which loses 50% of its activity at 55 degrees
FT                   Celsius."
FT                   /evidence="ECO:0000269|PubMed:17525463"
FT   MUTAGEN         360
FT                   /note="K->A: Exhibits no change in substrate affinity for
FT                   formate, but shows a 4-fold decrease in substrate affinity
FT                   for NAD implying that L-360 side chain forms strong
FT                   interactions with the cofactor. A higher reaction rate is
FT                   observed at an acidic and basic pH values."
FT                   /evidence="ECO:0000269|PubMed:11054119"
FT   CONFLICT        19..23
FT                   /note="KLYGC -> EKLYG (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        23
FT                   /note="C -> T (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   STRAND          2..6
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           12..16
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   TURN            24..26
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           27..29
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           31..36
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          40..45
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          49..52
FT                   /evidence="ECO:0007744|PDB:2FSS"
FT   HELIX           53..57
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           58..60
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          62..66
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           76..81
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          87..93
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           100..106
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          111..114
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           120..135
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           138..146
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           152..156
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          166..170
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           174..183
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           184..186
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          189..194
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           201..206
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          209..211
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           215..220
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          223..227
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   TURN            233..237
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           241..244
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          251..255
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           259..261
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           264..272
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          275..282
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          285..288
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           294..297
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          306..308
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           313..315
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           317..335
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   HELIX           343..345
FT                   /evidence="ECO:0007744|PDB:2J6I"
FT   STRAND          346..349
FT                   /evidence="ECO:0007744|PDB:2J6I"
SQ   SEQUENCE   364 AA;  40370 MW;  1B30982E0D5B77E8 CRC64;
     MKIVLVLYDA GKHAADEEKL YGCTENKLGI ANWLKDQGHE LITTSDKEGE TSELDKHIPD
     ADIIITTPFH PAYITKERLD KAKNLKLVVV AGVGSDHIDL DYINQTGKKI SVLEVTGSNV
     VSVAEHVVMT MLVLVRNFVP AHEQIINHDW EVAAIAKDAY DIEGKTIATI GAGRIGYRVL
     ERLLPFNPKE LLYYDYQALP KEAEEKVGAR RVENIEELVA QADIVTVNAP LHAGTKGLIN
     KELLSKFKKG AWLVNTARGA ICVAEDVAAA LESGQLRGYG GDVWFPQPAP KDHPWRDMRN
     KYGAGNAMTP HYSGTTLDAQ TRYAEGTKNI LESFFTGKFD YRPQDIILLN GEYVTKAYGK
     HDKK
//
